Certified by Founder Lodge
The Column Group
United States - San Francisco, CA
INVESTOR
1 Disclosed Funding Rounds $160,000,000
7 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
The Column Group (TCG) is a science-driven venture capital firm that makes significant financial and operational commitments to build early stage drug discovery companies based on their uniqu
| Company | Date | Round | Raised |
|---|---|---|---|
Carmot Therapeutics, Inc. |
July, 26 ,2022 | Series D | $160,000,000 |
Atavistik Bio |
December, 26 ,2023 | Unknown | $40,000,000 |
Remix Therapeutics |
January, 04 ,2024 | Unknown | $60,000,000 |
Tr1X |
January, 19 ,2024 | Series A | $75,000,000 |
Kenai Therapeutics |
March, 01 ,2024 | Series A | $28,000,000 |
A2 Biotherapeutics, Inc. |
January, 10 ,2025 | Series C | $80,000,000 |
Nilo Therapeutics |
October, 10 ,2025 | Series A | $101,000,000 |
Carmot Therapeutics, Inc.
Atavistik Bio
Remix Therapeutics
Tr1X
Kenai Therapeutics
A2 Biotherapeutics, Inc.
Nilo Therapeutics
Cherry Ventures
Blue Bear Capital
Slow Ventures
Climate Capital
Eniac Ventures
Sizable Energy | $8,000,000 | (Oct 24, 2025)
Sumble | $38,500,000 | (Oct 24, 2025)
Syntracts | $5,300,000 | (Oct 24, 2025)
Cybrid | $10,000,000 | (Oct 24, 2025)
Elevara Medicines | $70,000,000 | (Oct 24, 2025)